N2913

Sigma-Aldrich

N-TER Nanoparticle siRNA Transfection System

NACRES:
NA.51

Quality Level

shipped in

wet ice

storage temp.

−20°C

Application

The N-TER Nanoparticle siRNA Transfection System is a peptide-based system for use in the transient knockdown of eukaryotic gene expression. The N-TER Peptide binds siRNAs non-covalently, forming a nanoparticle. This nanoparticle interacts directly with lipids on the surface of the plasma membrane, allowing the nanoparticle to diffuse across the cell membrane and deliver the siRNA directly to the cytoplasm. Unlike most lipid-based transfection methods, this novel delivery mechanism bypasses the endosomal pathway, eliminating possible compartmentalization and degradation of the siRNA.

Legal Information

Manufactured and Distributed by Sigma-Aldrich, under license from the CNRS.
N-TER is a trademark of Sigma-Aldrich Co. LLC

RIDADR

NONH for all modes of transport

WGK Germany

nwg

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Sébastien Deshayes et al.
Advanced drug delivery reviews, 60(4-5), 537-547 (2007-11-27)
The recent discovery of new potent therapeutic molecules which do not reach the clinic due to poor delivery and low bioavailability have made of delivery a key stone in therapeutic development. Several technologies have been designed to improve cellular uptake...
L Crombez et al.
Biochemical Society transactions, 35(Pt 1), 44-46 (2007-01-20)
The major obstacle to clinical development of siRNAs (short interfering RNAs), like for most of the nucleic-acid-based strategies, is their poor cellular uptake and bioavailability. Although several viral and non-viral strategies have been proposed to improve siRNA delivery, their applications...
Linlu Tian et al.
Scientific reports, 5, 12357-12357 (2015-07-24)
Melanoma is one of the most aggressive skin cancers and is well known for its high metastatic rate. Studies have shown that epithelial mesenchymal transition (EMT) is essential for melanoma cell metastasis. However, the molecular mechanisms underlying EMT are still...
Federica Simeoni et al.
Nucleic acids research, 31(11), 2717-2724 (2003-05-29)
The improvement of non-viral-based gene delivery systems is of prime importance for the future of gene and antisense therapies. We have previously described a peptide-based gene delivery system, MPG, derived from the fusion peptide domain of HIV-1 gp41 protein and...
Joshua E Lewis et al.
Antioxidants & redox signaling, 29(10), 937-952 (2017-08-02)
The purpose of this study was to investigate differential nicotinamide adenine dinucleotide phosphate, reduced (NADPH) production between radiation-sensitive and -resistant head and neck squamous cell carcinoma (HNSCC) cell lines and whether these differences are predictive of sensitivity to the chemotherapeutic...
Articles
The field of proteomics is continually looking for new ways to investigate protein dynamics within complex biological samples. Recently, many researchers have begun to use RNA interference (RNAi) as a method of manipulating protein levels within their samples, but the ability to accurately determine these protein amounts remains a challenge. Fortunately, over the past decade, the field of proteomics has witnessed significant advances in the area of mass spectrometry. These advances, both in instrumentation and methodology, are providing researchers with sensitive assays for both identification and quantification of proteins within complex samples. This discussion will highlight some of these methodologies, namely the use of Multiple Reaction Monitoring (MRM) and Protein-AQUA.
Read More

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.